OnKure Therapeutics - Class A opened lower at $3.33, compared with its previous close of $3.36. In the last trading session, the stock traded between $2.99 and $3.33. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in OnKure Therapeutics - Class A is now worth
$ 16.14
Resulting in a loss of
$ 83.86 (83.86%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.35 (-10.42%)
Day High
$3.33
Day Low
$2.99
Day Open
$3.33
Prev Close
$3.36
Volume
2,63,398
1W Return
15.86%
1M Return
24.74%
3M Return
-26.33%
6M Return
-12.50%
1Y Return
-5.05%
Fundamentals
Market Cap ($ Mn)
122
PE Ratio
-
PB Ratio
0.89
PEG Ratio
-
ROE
-75.29%
ROCE
-79.34%
EPS (TTM)
-
Investment Returns
1 Week
15.86%
1 Month
24.74%
3 Months
-26.33%
6 Months
-12.50%
9 Months
22.36%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
5Nov
OnKure Therapeutics Q3 Results: EPS loss widens to $0.36, misses estimates
OnKure Therapeutics posted a Q3 EPS loss of $0.36, missing the $0.34 consensus estimate by 5.88%. The loss per share was reported as a 66.97% increase over the prior year's $1.09 loss. Analysts had anticipated a narrower loss than what was ultimately reported.
8 days ago
20Jul
HC Wainwright maintains Buy on OnKure, cuts target to $21
HC Wainwright & Co. analyst Robert Burns maintained a Buy rating on OnKure Therapeutics but reduced the price target to $21 from $27.
3mo ago
2Jul
OnKure Therapeutics to host virtual KOL event on July 15, 2026
OnKure Therapeutics announced a virtual KOL event on July 15, 2026, to discuss its PI3Kα inhibitor programs, featuring experts Benjamin F. Cravatt and Robert Abraham. The company will highlight its strategy for designing next-generation pan-mutant PI3Kα inhibitors, OKI-345 and OKI-355. OnKure plans to submit IND applications for these programs in the first half of 2027.
